Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29070960 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HRH4HTTHSD17B10HPGD | |
| SCHEMBL12416712 | 0.77 | PDGFRB (0.50) | HRH4POLB | |
| SCHEMBL21900465 | 0.77 | CYP1A2 (0.41) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL22778437 | 0.73 | DGAT1 (0.39) | — | |
| SCHEMBL23478912 | 0.73 | HRH4 (0.38) | CCR9ALDH1A1HRH4HSD17B10HPGD | |
| SCHEMBL10243492 | 0.72 | OGA (0.41) | ALDH1A1MEN1PABPC1KMT2A | |
| SCHEMBL799552 | 0.71 | CYP19A1 (0.41) | LMNAPOLBRAB9AATML3MBTL1 | |
| SCHEMBL4146607 | 0.71 | BRD4 (0.44) | — | |
| SCHEMBL13165466 | 0.70 | ALDH1A1 (0.44) | ALDH1A1HTTLMNAKMT2APOLB | |
| SCHEMBL14803730 | 0.70 | POLB (0.38) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870630-B2 | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2020-12-22 | — | — | US | disclosed |
| US-20190308945-A1 | SUBSTITUTED BICYCLIC HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870630-B2 | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | CCR9 1449/4885ALDH1A1 2403/4885HRH4 342/4885 |
| US-20190308945-A1 | SUBSTITUTED BICYCLIC HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA2 | CCR9 1449/4885ALDH1A1 2403/4885HRH4 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.